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Abstract
Objective: During surgery for colon carcinoma, tumour cells may spread into the blood andmay lead to the development of distantmetastases.
The most frequent sites of metastases are the liver and lungs. A new therapeutic approach is required to prevent tumour implantation of freely
circulating tumour cells during and after surgery and to treat established metastases. The aim of this prospective study was to observe the
influence of long-term intravenous taurolidine on the development of lung metastases after intravenous injection of colon adenocarcinoma cells.
Methods: Tumour cells (DHD/K12/TRb colon adenocarcinoma cell line, 1  106 cells) were injected into the right vena jugularis interna of BDIX
rats. The animals (n = 13) were randomised into three groups: group 1: tumour cell implantation without taurolidine application (control group);
group 2: tumour cell implantation and simultaneous start of the taurolidine injection through osmotic pump, removal of the osmotic pump on day
7; group 3: tumour cell implantation on day 0 and start of the taurolidine injection through osmotic pump on day 14. Results: In the taurolidine
groups, the number and size of lung metastases were significantly lower compared to the control group (p = 0.018; p = 0.018 and p = 0.036;
p = 0.018). Although the results of the intravenous long-term therapy with taurolidine in group 2 did not reach statistical significance in
comparison with the results of group 3, a positive trend was revealed: The mean number of metastases in group 2 was 18.2 versus 28.2 in group 3.
Conclusions: The application of taurolidine tends to prevent the development of lung metastases. Furthermore, taurolidine seems to reduce
established lung metastases in this in vivo model. Taurolidine may offer additional therapeutic options in patients with colon adenocarcinoma.
# 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Colon adenocarcinoma is one of the leading causes of
death by malignancy in Europe and the USA [1]. In the case of
a curative treatment option, surgical resection remains the
primary treatment modality for this cancer. During surgery,
tumour cells may spread and may lead to both loco-regional
recurrences and/or distant metastases [2—4]. More than 50%
of all patients undergoing surgery for colon carcinoma can be
expected to have a recurrence of the disease. The most
frequent sites of recurrence are the liver and lungs: About
10% of the patients with a colon adenocarcinoma will develop
lung metastases [5].
On the basis of this knowledge, the effect of taurolidine on
the development of haematogenous adenocarcinoma metas-
tases was examined in an experimental study with BDIX rats.
Taurolidine has anti-adhesive and anti-angiogenetic effects
and induces apoptosis [6,7]. Up till now the majority of in* Corresponding author. Tel.: +41 31 632 3096; fax: +41 31 632 2327.
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doi:10.1016/j.ejcts.2009.04.065vivo trials for the investigation of taurolidine and its impact
on tumour development with colon adenocarcinoma cell lines
deals with intra-peritoneal or subcutaneous growth [8,6,9].
The aim of this prospective study was to observe the
influence of a long-term intravenous taurolidine injection on
the development of lung metastases after intravenous
injection of adenocarcinoma cells.
2. Material and methods
2.1. Animals
BDIX rats weighing 275—380 g (Charles River GmbH,
Sulzfeld, Germany) were used. The animals were kept in
single cages under standardised conditions with constant
temperature (22  1 8C), humidity (50—60%) and a 12:2 h
light/dark cycle. Animals had free access to water and food.
They received humane care in compliance with the European
Convention on Animal Care, and the experiment was
approved by the local veterinary committee (No.: 25/04).urgery. Published by Elsevier B.V. All rights reserved.
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The DHD/K12/TRb colon adenocarcinoma cell line was
used. The cell line was bought from the Center for Applied
Microbiology & Research, ECACC (European Collection of Cell
Cultures), Salisbury, UK. Cells were cultured in Dulbecco’s
MEM (Invitrogen AG, CH-4019 Basel, Switzerland), supple-
mented with penicillin, streptomycin (Invitrogen AG, CH-
4019 Basel, Switzerland), and 5% CO2 (37 8C). Cells were
removed from the plates with 0.05% trypsin/0.02% EDTA,
washed twice with PBS, suspended in medium, centrifuged
and re-suspended in medium to the desired concentration.
For tumour implantation, a cell suspension containing
1  106 cells was prepared and the number of cells was
controlled by a Neubauer-Za¨hlkammer.
2.3. Application of taurolidine
A 2-ml taurolidine 2% (Geistlich Pharma AG, CH-6110
Wolhusen, Switzerland) was applied intravenously through a
minipump (ALZETW Osmotic Pumps, 2 ml, Charles River
Laboratories, Germany) continuously for 7 days. The osmotic
pumps were prepared by following the instructions of Charles
River Laboratories and were connected to the jugular vein by
a special Rat Jugular Catheter (31/2 51/4, Carl Parker
Associates, New York, USA).
2.4. Anaesthesia
After induction of anaesthesia in an isofluran chamber, the
animals received an intra-peritoneal application of
50 mg kg1 pentobarbital.
During the surgery, the animals were placed on a heating
pad.
2.5. Tumour induction
To provide evidence for tumour growth, we started a pilot
study with two animals. These animals were sacrificed after
tumour cell application on day 10 and day 15, respectively.Fig. 1. Lung metastases (H.E.).Both showed extensive dissemination of lung metastases
(Fig. 1).
2.6. Animals and experimental groups
In the experimental prospective study, animals were
randomised into three groups — group 1: tumour cell
implantation (1  106 cells) without taurolidine application
(control group); group 2: tumour cell implantation (1  106
cells) with simultaneous taurolidine application from day 0 to
day 7, and removal of the osmotic pump on day 7; and group
3: tumour cell implantation (1  106 cells) with subsequent
taurolidine application from day 14 to day 21.
Under anaesthesia, an incision was made on the right side
of the neck and thorax (2 cm). The right vena jugularis
interna was prepared. By venotomy, a small catheter was
introduced and the tumour cell suspension was injected, and
then the catheter was removed in groups 1and 3 (Fig. 2).
In group 2, the prepared and filled osmotic pumps were
implanted immediately after injection of the tumour cells.
The special Rat Jugular Catheter was inserted by the same
venotomy and fixed. For the osmotic pump, a small
subcutaneous chamber was dissected on the back and the
skin was closed. Seven days later, the empty osmotic pump
was removed (anaesthesia as described above).
Animals of group 3 received the osmotic pump 14 days
after tumour cell inoculation. The previous skin incision was
re-opened, the right vena jugularis dissected and the pumpFig. 2. Application of the tumor cells.
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Fig. 3. Implantation of the osmotic pump/catheter in the right versus jugu-
laris.
Table 1
Groups of animals and histological analysis/evidence (*) of lung metastases.
n Lung metastases* (%)
Group 1 (control) 3 100
Group 2 5 60
Group 3 5 80
Fig. 4. Number of lung metastases in the different groups.was implanted in the same way as described for animals in
group 2 (Fig. 3a and b).
Group 1 served as the control group.
On the 21st day, animals were sacrificed under anaes-
thesia with pentobarbital.
2.7. Data analysis
The primary end point was the extent of lung metastases
(size and number) in groups 2 and 3 in comparison with group
1 (control group).The secondary end point was the extent of lung
metastases (size and number) in group 2 in comparison with
group 3.
2.8. Methods
The whole lungs were embedded in formaldehyde.
Specimens were cut at 5 mm on defined levels in a distention
of 100 mm (Leica RM 2155) and stainedwith haematoxylin and
eosin (H.E.) for histological examination. The number and
size (mm2) of the metastases were registered (Nikon Eclipse E
800, Nikon DXM 1200 and PC program Lucia Image 5.1).
2.9. Statistics
Statistical analysis was carried out with the Wilcoxon
rank-sum tests with a one-sided alternative hypothesis. No
correction for multiple comparisons was performed.
Generally, p-values less than 0.05 were considered
significant.
3. Results
3.1. Groups of animals and histological analysis of lung
metastases
Table 1 shows the number of animals in each group and the
development of lung metastases in the animals.
3.2. Number of lung metastases in all groups
In both taurolidine groups, the number of lung metastases
was significantly lower compared with the control group
( p = 0.018; p = 0.018) (Fig. 4 and Table 2).
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Table 2
Number and size (mm2) of the lung metastases in the different groups Ø = mean, S = total/sum size of metastases in mm2.
Group 1 (control) Group 2 Group 3
Number of
metastases
Size of metastases Number of
metastases
Size of metastases Number of
metastases
Size of metastases
1 491 66584556 1 7 927414 1 83 8878149
2 772 60478044 2 73 14480149 2 0 0
3 134 9851381 3 11 1046878 3 5 537134
— 4 0 0 4 35 3277246
— 5 0 0 5 18 2399775
S1397 S136913981 S91 S16454441 S141 S15092304
Ø465.7  319.8 Ø45637993.7 Ø18.2  31.0 Ø3290368.2 Ø28.2  33.5 Ø3018460.8
Fig. 5. Sum total of the size (mm2) of lung metastases in the different groups.Between groups 2 and 3, there was no significant
difference with respect to the number of the lung metastases
( p = 0.270).
3.3. Sum total size of lung metastases in all groups
The size of the lung metastases was significantly higher in
the control group compared with groups 2 and 3 ( p = 0.036;
p = 0.018) (Fig. 5 and Table 2).
There was no significant difference between the taur-
olidine groups with respect to the size of metastases
( p = 0.345).
4. Discussion
In the developed countries, colon carcinoma ranks first for
incidence among gastrointestinal malignancies [10]. In
general, patients with curatively resected colon cancer
without a tumour involvement of the lymph nodes do not
receive adjuvant chemotherapy. However, approximately
30—40% of these patients will develop loco-regional and/or
distant metastases in the follow-up [1,11]. One explanation
could be an incomplete lymph node staging or the missing of
micro-metastases by classic histopathological examination
[11]. However, another cause for this problem may be the
release of tumour cells during the surgical resection. These
free tumour cells can adhere, implant and grow — locally and
distantly. Even if freely circulating tumour cells do not induce
the development of local tumour recurrences or metastasesin every case, they are potential sources of tumour spread in
the long term [12]. The hypothesis of tumour cell implanta-
tion by released free tumour cells has been verified in
different trials in vitro and in vivo [2—4]. Koch et al. showed
that free tumour cells found in blood samples during and
after the operation led to a poorer outcome in comparison
with patients without free tumour cells in the blood [3]. Parts
of the underlying complex process of the development of
metastases are known, such as cell adhesion, tumour cell
invasion through the basement membrane and neoangiogen-
esis [2].
The pulmonary metastasectomy, in case of colon carci-
noma, is an established technique in the multidisciplinary
concept, but feasible only in 50% of the patients. In the case
of complete resection, the 5-year survival rate ranged
between 38.3% and 63.7% in comparison with those cases in
which a resection was impossible (13%) [1,13]. A palliative
chemotherapy (without resection of the lung metastases)
shows survival rates of less than 15 months [14].
These statistics indicate a need for a new therapeutic
approach to prevent tumour implantation of freely circulat-
ing tumour cells during and after surgery. The question is
whether the application of a specific (cytotoxic) substance
prevents the development of metastases in patients with
colon adenocarcinoma. Taurolidine (a derivate of the amino
acid taurine) has been widely used for treating severe
infections such as peritonitis and pleural empyema for more
than 25 years [2]. However, taurolidine has also been widely
described for antineoplastic treatment in different cancer
cell lines: Braumann et al. demonstrated a down-regulation
of subcutaneous tumour growth (colon adenocarcinoma cell
line DHD/K12/TRb cells) with an intravenous long-term
therapy of 3% taurolidine [8]. Opitz et al. were able to show a
significant reduction of local recurrence of malignant pleural
mesothelioma using an intrapleural taurolidine treatment
[15]. Kilian et al. inhibited tumour growth in ductal
pancreatic adenocarcinoma by laparoscopic irrigation with
taurolidine [16]. The effects of taurolidine are manifold.
Amongst others, taurolidine is known to have anti-adhesive
as well as anti-angiogenetic properties [6,7]. It has been
shown that long-term treatment with taurolidine can induce
apoptosis [6,8]. The apoptosis could be partially caused by a
mitochondrial cytochrome c-dependent apoptotic mechan-
ism [17]. Furthermore, taurolidine reduces the production of
vascular endothelial growth factor (VEGF), a major pro-
angiogenetic factor [8]. Additionally, taurolidine exerts a
direct effect on glial and neuronal brain tumour cells through
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et al. and Van Antwerp et al. found a decrease of tumour
necrosis factor alpha (TNFa) and interleukin-1b after
taurolidine treatment [19,20].
Up to now, all known in vivo trials for the investigation of
taurolidine and its impact on tumour development with colon
adenocarcinoma cell lines deal with intra-peritoneal or
subcutaneous growth [8,6,9,16,21]. Therefore, the devel-
opment of lung metastases with the colon adenocarcinoma
cell line DHD/K12/TRb had to be established in a first pilot
phase. The spreading of free tumour cells was simulated by
the direct injection of the tumour cell suspension of DHD/
K12/TRb into the right vena jugularis. The cells went directly
into the lungs and constituted lung metastases. Thereby, a
model of colon adenocarcinoma lung metastases in BDIX rats
was successfully established: In the pilot study, the animals
showed lung metastases on day 10 and day 15, respectively,
which means that lung metastases developed within 2 weeks.
This model allowed the effect of a continuous injection of
taurolidine 2% in view of the development of lung metastases
to be evaluated. All animals (100%) in the control group
developed lung metastases in comparison with the treatment
groups with 60% (group 2) and 80% (group 3), respectively. In
the two groups with a taurolidine treatment, both the
number and size of the lung metastases were significantly
decreased in comparison with the control group. Although
the results of intravenous long-term therapy with taurolidine
in group 2 did not reach statistical significance in comparison
with the results of group 3, a positive trend for the number of
metastases was found (mean of group 2: 18.2 vs mean of
group 3: 28.2). This means taurolidine may be a potential
substance for preventing lung metastases when the applica-
tion starts parallel to the releasing of free tumour cells, for
example, during the primary colon resection. Furthermore,
taurolidine may not only have the potential to prevent lung
metastases of colon adenocarcinoma, but may also be used in
their treatment: all the animals in the control group
developed lung metastases, with a mean number of 465.7.
In the case of treatment starting 2 weeks after tumour cell
spread (group 3), one animal did not show lung metastases,
another one had only five metastases. The mean number of
metastases in group 3 was 28.2.
The sample size of this study is small. One reason for this is
the high price of the osmotic pumps. To our knowledge, this
trial is the first one showing the clear effect of taurolidine on
lung metastases of colon adenocarcinoma in an animal
model. This fact should be taken as an incentive for further
studies.
5. Conclusion
To improve the outcome for patients with pulmonary
metastatic colon adenocarcinoma, new concepts must be
evaluated. The application of taurolidine tends to prevent
the development of lung metastases and reduces the tumour
growth in this in vivo model. Therefore, taurolidine
represents an interesting substance for a multimodal
approach in the therapy of colon adenocarcinoma even in
the case of stages I and II (N0-status), in which adjuvant
chemotherapy after the surgical resection is not regularlyrecommended. Taurolidine may offer additional therapeutic
options to prevent or treat lung metastases in the follow-up
after surgical resection of colon adenocarcinoma.
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